Development of reporting guidance and core outcome sets for seamless, standardised evaluation of innovative surgical procedures and devices:A study protocol for content generation and a Delphi consensus process (COHESIVE study) by Avery, Kerry et al.
                          Avery, K., Blazeby, J., Wilson, N., Macefield, R., Cousins, S., Main, B., ...
Potter, S. (2019). Development of reporting guidance and core outcome sets
for seamless, standardised evaluation of innovative surgical procedures and
devices: a study protocol for content generation and a Delphi consensus
process (COHESIVE study). BMJ Open, 9(e029574), e029574.
https://doi.org/10.1136/bmjopen-2019-029574
Publisher's PDF, also known as Version of record
License (if available):
CC BY
Link to published version (if available):
10.1136/bmjopen-2019-029574
Link to publication record in Explore Bristol Research
PDF-document
This is the final published version of the article (version of record). It first appeared online via BMJ at
http://dx.doi.org/10.1136/bmjopen-2019-029574 . Please refer to any applicable terms of use of the publisher.
University of Bristol - Explore Bristol Research
General rights
This document is made available in accordance with publisher policies. Please cite only the published
version using the reference above. Full terms of use are available:
http://www.bristol.ac.uk/pure/about/ebr-terms
1Avery K, et al. BMJ Open 2019;9:e029574. doi:10.1136/bmjopen-2019-029574
Open access 
Development of reporting guidance and 
core outcome sets for seamless, 
standardised evaluation of innovative 
surgical procedures and devices: a study 
protocol for content generation and a 
Delphi consensus process 
(COHESIVE study)
Kerry Avery,   1 Jane Blazeby,1,2 Nicholas Wilson,1 Rhiannon Macefield,1 
Sian Cousins,1 Barry Main,   1,2 Natalie S Blencowe,   1,2 Jesmond Zahra,1 
Daisy Elliott,1 Robert Hinchliffe,1,3 Shelley Potter   1,4
To cite: Avery K, Blazeby J, 
Wilson N, et al.  Development 
of reporting guidance and core 
outcome sets for seamless, 
standardised evaluation of 
innovative surgical procedures 
and devices: a study protocol 
for content generation and 
a Delphi consensus process 
(COHESIVE study). BMJ Open 
2019;9:e029574. doi:10.1136/
bmjopen-2019-029574
 ► Prepublication history for 
this paper is available online. 
To view these files please visit 
the journal online (http:// dx. doi. 
org/ 10. 1136/ bmjopen- 2019- 
029574).
KA and SP contributed equally.
Received 31 January 2019
Revised 20 June 2019
Accepted 09 July 2019
For numbered affiliations see 
end of article.
Correspondence to
Dr Kerry Avery;  
 kerry. avery@ bristol. ac. uk
Protocol
© Author(s) (or their 
employer(s)) 2019. Re-use 
permitted under CC BY. 
Published by BMJ.
Strengths and limitations of this study
 ► Consensus methods will be used to develop guid-
ance and core outcome sets (COS) for seamless, 
standardised evaluation and reporting of outcomes 
of innovative invasive procedures and medical 
devices.
 ► Guidance and COS(s) will be developed with multi-
national, multi-stakeholder input, including patients, 
surgeons, device manufacturers, regulators, meth-
odologists and journal editors.
 ► Multiple novel data sources beyond traditional sys-
tematic reviews will generate a list of guidance 
items and outcomes of relevance to evaluating in-
novative procedures and devices.
 ► An integrated randomised methodological study will 
investigate methods for optimally achieving consen-
sus during Delphi surveys.
 ► Further work is needed to explore how to optimal-
ly implement and monitor use of the guidance and 
COS(s).
AbStrACt
Introduction Rigorous evaluation of innovative invasive 
procedures and medical devices is uncommon and lacks 
reporting standardisation. Devices may therefore enter 
routine practice without thorough evaluation, resulting 
in patient harm. Detailed guidance on how to select and 
report outcomes at each stage of evaluation is lacking. 
Development of reporting guidance and core outcome 
sets (COS) is one strategy to promote safe and transparent 
evaluation.
Methods and analysis A COS, comprising outcome 
domains applicable to all phases of evaluation of 
procedure/device introduction and modification and, if 
necessary, supplementary domains relevant to specific 
phases or types of innovation (procedure or device), will 
be developed according to principles outlined by Core 
Outcome Measures in Effectiveness Trials (COMET) and 
Core Outcome Set-Standards for Development (COS-
STAD) guidelines. Reporting guidance will be developed 
concurrently. The study will have the following three 
phases:
1. Generation of a list of relevant outcome domains and 
reporting items identified from (a) published studies, 
(b) hospital policy documentation, (c) regulatory body 
documentation and (d) stakeholder qualitative interviews. 
Identified items/domains will be categorised using 
a conceptual framework and formatted into Delphi 
consensus survey questionnaire items.
2. Key stakeholders, including 50 patients and 
150 professionals (surgeons, researchers, device 
manufacturers, regulatory representatives, journal editors) 
sampled from multinational sources, will complete a 
Delphi survey to score the importance of each reporting 
item and outcome.
3. A consensus meeting with key stakeholders will discuss 
and agree the final content of the reporting guidance and 
COS(s).
Ethics and dissemination Ethical approval has been 
granted by North East-Newcastle and North Tyneside 1 
Health Research Authority Research Ethics Committee 
(18/NE/0378). Dissemination strategies include scientific 
meeting presentations, peer-reviewed journal publications, 
development of plain English summaries/materials, patient 
engagement events, development of a social media 
identity, workshops and other events.
IntroduCtIon
Methods for introducing innovative invasive 
(surgical) procedures and medical devices 
(any devices used inside the body including 
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implantable surgical devices, eg, pacemakers, mesh, 
implants) into clinical practice are not optimally regu-
lated. Rigorous early evaluation of procedures/devices 
is uncommon, and reporting of outcomes is neither 
comprehensive nor standardised.1 Suboptimal regula-
tion and reporting has resulted in compromised patient 
safety,2–4 highlighting the need for robust, transparent 
methods for safe and efficient innovation.1
The IDEAL framework was published in 2009 to 
improve the evaluation of invasive surgical procedures 
from first in man use to long-term study.5 More recently, 
IDEAL-D has been introduced to facilitate the evaluation 
of medical devices.6 Adoption of IDEAL/IDEAL-D by the 
surgical community has been slow.7 Reasons for this may 
be attributed to lack of understanding around applying 
the framework in practice.7 Guidance on selecting, 
measuring and reporting outcomes relevant to evalu-
ating invasive procedures/devices during specific stages 
of their introduction and modification is also lacking. 
Comprehensive evaluation and reporting would allow 
learning to be shared across the surgical community and 
enhance transparency, allowing promising innovations to 
be identified more rapidly and unsafe or harmful proce-
dures/devices to be abandoned before they become 
established into routine clinical practice. Streamlined 
mechanisms for evaluating breakthrough technologies 
and treatments and speeding up their adoption is the 
primary objective of the UK government’s Accelerated 
Access Review to improve patient outcomes.8 Appro-
priate outcome selection is integral to these processes. 
Development of guidance and a generic core outcome 
set (COS: a minimum set of outcome domains to be 
reported in all uses in clinical practice, studies or audits) 
may be one strategy by which safe and efficient introduc-
tion and modification of novel procedures/devices can 
be achieved.
While methods for developing COS for effectiveness 
studies are well established, it is unclear whether these 
methods will be applicable to developing a COS for 
innovative invasive procedures/devices. The process of 
selecting outcomes for effectiveness studies, in which the 
intervention under evaluation is expected to be stable, 
is unlikely to identify outcomes of specific relevance to 
innovation, such as technique modification or abandon-
ment. It is also important that some outcomes included 
within the COS are valid throughout all stages of eval-
uation to allow for earlier identification of longer-term 
adverse events. To achieve this, it is hypothesised that 
a modular COS approach may be needed to capture 
outcomes relevant to different stages of evaluation. 
This may include a central generic COS that would 
be measured and reported in all uses and evaluations, 
supplemented by bolt-on COSs relevant to specific 
phases of innovation and/or evaluation, and, if neces-
sary, the specific disease or intervention. The necessity 
and framework for a modular COS approach will be eval-
uated throughout the study.
Aim
The Core Outcomes for early pHasE Surgical Innovation 
and deVicEs (COHESIVE) study will develop reporting 
guidance and a COS(s) for seamless, standardised 
outcome evaluation of innovative procedures and devices.
MEthodS And AnAlySIS
overview
The COS(s) will be developed according to the Core 
Outcome Measures for Effectiveness Trials (COMET) 
Handbook9 and the Core Outcome Set-STAndards for 
Development (COS-STAD) guidelines.10 Reporting guid-
ance will be developed concurrently. The study will have 
three phases:
1. Generation of a comprehensive list of reporting guid-
ance content (eg, items relating to guidance about 
additional detail required when reporting a specific 
outcome) and outcome domains from multiple data 
sources.
2. Prioritisation of identified items using a multistage, in-
ternational stakeholder Delphi survey.
3. A stakeholder consensus meeting to discuss, agree and 
ratify the final guidance and COS(s).
Reporting guidance will be developed in line with 
existing methodologies,11 including involvement of an 
executive group, Delphi consensus methods and a face-
to-face meeting of stakeholders to maximise the robust-
ness of guidance development.
Patient and public involvement
Patients and members of the public will be involved 
throughout. A patient and public involvement (PPI) 
group has been established as part of the National Institute 
for Health Research (NIHR) Bristol Biomedical Research 
Centre (BRC) Surgical Innovation theme (of which this 
study is a part). Two patients have been appointed to the 
study steering group and will be invited to contribute to 
all study phases and discuss dissemination of the findings.
Scope of the guidance and CoS(s)
The reporting guidance and COS(s) will support stan-
dardised evaluation of innovative invasive procedures/
devices. The COS(s) will apply to routine clinical prac-
tice, audit and research settings where introduction and 
modification of invasive procedures/devices occur prior 
to definitive evaluation within a pragmatic randomised 
controlled trial.5 It is anticipated, however, that some 
outcomes will be ‘core’ to stages of evaluation beyond 
introduction and modification (eg, including registries 
and long-term studies) to allow key outcomes to be eval-
uated from the earliest studies of an invasive procedure/
device. The guidance and COS(s) will be developed for 
use by key stakeholders involved in the introduction, 
modification, evaluation or reporting of innovative inva-
sive procedures/devices, including surgeons, device 
manufacturers, regulators, trialists, methodologists and 
journal editors.
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definition of an invasive procedure and medical device
An invasive procedure is defined as one where access is 
gained via an incision, natural orifice or percutaneous 
puncture or involving devices used inside the body.12 An 
invasive medical device will be further defined as one that 
is inserted into and remains within the body with the aim 
of achieving a therapeutic function.
definition of an ‘innovation’ outcome
While work to develop a definition of surgical innovation is 
ongoing,12 no single definition of surgical innovation has 
yet been widely adopted. The COMET Handbook defines 
an outcome as a measurement or observation used to 
capture and assess the effect of treatment such as assess-
ment of side effects (risk) or effectiveness (benefits).9 
Although relevant for effectiveness trials, this definition 
is unlikely to capture all issues of relevance to evaluation 
of novel invasive procedures/devices.13 Preliminary work 
by the study team indicates that, in addition to estab-
lished effectiveness outcomes, additional outcomes may 
be required to fully evaluate the process and effects of 
innovation, such as modification or abandonment of the 
technique/device.14 An innovation outcome will there-
fore be defined as a measurable variable (eg, construct or 
concept) related to or occurring as a result of the use of 
a novel invasive procedure/device. An outcome domain 
will be defined as a group of individual outcomes.13
Stakeholder involvement
A workshop funded by the Medical Research Council Hubs 
for Trials Methodology Research Network was convened 
in Bristol, UK, in September 2018. The workshop brought 
together 61 key stakeholders, including surgeons, repre-
sentatives from funding bodies, device industries and 
small and medium sized enterprises, trialists, methodol-
ogists, journal editors, regulators and patient representa-
tives, to consider core outcome reporting. Stakeholders 
represented several countries, including the UK, USA, 
Canada and Australia. The workshop concluded that 
development of reporting guidance and a COS(s) for 
innovative surgical procedures and devices via methods 
described in this study would be feasible and warranted 
further study.
The guidance and COS(s) will be developed with input 
from multiple stakeholder groups at all stages, to ensure 
that outcomes of relevance to all are included and for 
the COS to be widely adopted.9 Primary stakeholders, 
recruited from international sources, will include the 
following:
 ► Patients with experience of surgery and/or under-
going innovative surgical procedures.
 ► Surgeons (those involved/not in delivering innova-
tive procedures/devices).
 ► Device manufacturers and members of industry.
 ► Representatives of regulatory bodies and policy 
makers.
 ► Journal editors.
 ► Methodologists and trialists responsible for designing 
studies involving innovative invasive procedures/
devices.
A study steering group comprising stakeholder repre-
sentatives from the UK and internationally will be 
convened to provide overall oversight of the study.
Phase I: generation of a list of outcome and reporting domains
As innovation outcomes are conceptually different from 
those measured in effectiveness trials, standard methods9 
for identifying outcomes for inclusion in the list will be 
modified to include data sources hypothesised to be of 
specific relevance to innovation.
Targeted review of outcome selection and reporting 
recommendations in international regulatory body documentation
Online searches will identify advisory documents from 
prominent regulatory bodies of relevance to innovation 
of invasive procedures/devices, including the US Food 
and Drug Administration, UK Medicines and Healthcare 
products Regulatory Agency, UK National Institute for 
Health and Care Excellence Interventional Procedures 
Advisory Committee, EU Notified Bodies and Conformité 
Européene (CE) marking guidance to explore existing 
recommendations regarding outcome selection and 
reporting. Documents will be reviewed, and data relating 
to outcome selection and reporting extracted verbatim.
Focused literature reviews of outcome selection and reporting in 
published studies of invasive procedures/devices
A series of focused literature reviews will explore outcome 
selection and reporting in studies of innovative invasive 
procedure/devices.
Case studies of innovative devices
Case studies of innovative devices will be purposively 
selected by the study team to include a range of special-
ties and varying degrees of innovation (wholly innova-
tive—defined as a device that represents a completely new 
approach to solving a clinical problem; partially innova-
tive—defined as a device that is broadly similar in function 
to one already in use but differs in at least one significant 
way; reinvented—defined as a modification of a device or 
technique that was previously abandoned for complica-
tions). A focused PubMed search will be performed using 
the tradename of each identified device and reference 
lists of identified papers, reviews and commentaries to 
identify potentially relevant studies. Only primary studies 
specifically related to the device under evaluation will 
be included. Data regarding study design and timing 
of evaluation in the device lifecycle (eg, pre-market vs 
post-market) will be extracted. Outcomes selected and 
reported in each study will be extracted verbatim, and 
pre-marketing and post-marketing studies compared to 
explore whether outcome selection and reporting differs 
over time and to inform development of the reporting 
guidance and COS(s).
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Studies conducted within the IDEAL and IDEAL-D frameworks
It is hypothesised that studies self-identifying as IDEAL5 
or IDEAL-D6 (ie, where authors self-report that the study 
aligns with a stage of the IDEAL/IDEAL-D framework) 
may have more formally considered outcome selection 
in the context of innovation and may therefore provide 
greater insight into potential ‘innovation’ outcomes. 
Studies citing the three original 2009 Lancet publica-
tions,5 15 16 subsequent explanatory documents17–22 or 
the IDEAL-D paper6 will be identified through the Web 
of Science and Scopus databases. All primary papers 
self-identifying as IDEAL/IDEAL-D studies in the title or 
abstract will be included. Outcomes selected and reported 
in each study will be extracted verbatim and, if possible, 
compared across IDEAL stages (1, 2a, 2b) to explore if 
different outcomes are evaluated at different stages of 
innovation and to inform development of the reporting 
guidance and COS(s).
Review of recommendations for outcome selection and reporting 
in NHS trust policy documents
Written NHS Trust policy documents for the introduction 
of new invasive procedures/devices into clinical practice 
will be reviewed to explore current requirements for 
outcome selection and reporting within the NHS gover-
nance framework. Documents will be identified from 
related work ongoing in the NIHR Bristol BRC Surgical 
Innovation theme. Documents will be requested from 
all acute NHS Trusts in England and Health Boards in 
Wales. Initially, purposive sampling will be used to sample 
Trusts based on type, geographical location and foun-
dation status. All outcomes relating to the evaluation of 
innovative devices will be extracted verbatim. Purposive 
sampling will continue until new outcomes cease to be 
identified (data saturation).
Review of transcripts of qualitative interviews with patients and 
surgeons
Transcripts of audio-recordings from a purposive sample 
of qualitative interviews with key stakeholders (eg, 
patients, surgeons and industry representatives) will be 
reviewed to identify additional outcomes of relevance 
that have not been identified from other data sources. 
These interviews are being conducted for related work 
undertaken in the NIHR Bristol BRC Surgical Innovation 
theme.
Conceptualisation of outcome domains and reporting items
Verbatim outcomes identified from each data source 
will be used to create a comprehensive list of poten-
tial outcomes relevant to the evaluation of novel inva-
sive procedures/devices. Preliminary work by the study 
group has demonstrated the importance of context (eg, 
specialty and innovation stage) to outcome classifica-
tion for invasive procedure/device studies. A conceptual 
framework of outcome domains will therefore be gener-
ated and iteratively modified using each case study and 
data source in turn until saturation is reached (ie, no new 
outcomes emerge). Conceptualisation will be undertaken 
independently by members of the study team, followed by 
a meeting to review, discuss and modify the framework. 
Conceptualisation, review and refinement will be under-
taken iteratively until data saturation is achieved and the 
list is considered complete.
Content relevant to inform development of the 
reporting guidance will be accumulated and iteratively 
refined through ongoing discussion within the team. 
Guidance content and formatting will be informed by a 
targeted review of relevant research guidance documents 
(eg, IDEAL, CONsolidated Standards Of Reporting 
Trials/CONSORT statement and CONSORT extensions).
Phase II: prioritisation of identified reporting items and 
outcome domains using a multi-stakeholder delphi survey
A consensus process involving a sequential, multi-round 
Delphi survey followed by a face-to-face consensus 
meeting will be used to establish agreement between a 
multi-stakeholder group of patients and professionals 
on the final set of outcome domains to be included in 
the COS(s). To avoid any effect of dominant individuals, 
a Delphi survey consensus process will allow a diverse 
representative sample of key stakeholders from a broad 
geographical area to participate anonymously.9
Development of the Delphi survey questionnaire
Each outcome domain included in the final outcomes 
list detailed above will be operationalised and formatted 
into an item for the survey questionnaire. Each item will 
have a 9-point Likert scoring scale ranging from 1 (not 
important) to 9 (extremely important), based on the 
Grading of Recommendations Assessment, Develop-
ment and Evaluation scale for scoring the importance of 
including the item in the final COS.23 A free text item will 
be included to enable participants to propose new items. 
Additional outcome domains/items proposed by partic-
ipants in round 1 will be reviewed by the study team to 
confirm that they are new and formatted into a survey item 
for subsequent round(s) if they are recommended by at 
least two participants.24 Any uncertainties will be resolved 
by the study steering group. To ensure that the survey is 
suitable for completion by all stakeholders, items will be 
written in plain English with medical terminology and/
or examples (where applicable) included in parentheses. 
The draft survey will be piloted by two professionals (eg, 
surgeons) and two members of the PPI group, to examine 
its face validity (eg, comprehensibility and acceptability) 
and refine terminology, layout and formatting prior to 
commencing the main study. Professionals will receive a 
version of the Delphi survey also including items related 
to reporting guidance content, which will be operation-
alised and formatted in a similar manner to outcomes.
Participant sampling and invitations
Representatives from all key stakeholder groups detailed 
above will be invited to participate. Patients who are 
currently or who have previously participated in surgical 
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studies conducted by the Bristol Clinical Trials and 
Evaluation Unit will be invited to participate. Patients 
will be purposively sampled based on their gender, age, 
geographical region and study/procedure received to 
enable a broadly representative sample of participants 
with a range of experiences of different types of surgery 
to be included. Professional participants will be sampled 
to ensure inclusion of participants with various profes-
sional backgrounds and from broad geographical areas 
nationally and internationally. Professional participants 
will be identified through expert knowledge of colleagues 
(eg, known surgeons, specialty professional associations, 
industry collaborators and device manufacturers), contact 
lists held by the Centre for Surgical Research (University 
of Bristol) of attendees at topic-related academic events 
(eg, attendees at relevant conferences/workshops) and 
review of websites and other public resources. Additional 
patient and professional participants will be identified 
through opt-in to the Delphi survey via the COHESIVE 
study website, which will be further advertised through 
specialty professional associations described above.
Delphi survey rounds
Participants will complete up to three sequential rounds 
of the survey questionnaire over a 3–9 months period. 
In each round, participants will score the importance 
of including the item in a COS (and reporting guid-
ance—professionals only). Survey questionnaires will be 
predominantly administered online, hosted by secure 
REDCap electronic data capture software.25 Adminis-
tration and reporting of the electronic survey will be 
conducted in accordance with the Checklist for Reporting 
Results of Internet E-Surveys guidelines.26 Paper surveys 
will be sent to those who are unable to complete the 
survey electronically.
All participants who complete the round 1 question-
naire will be sent the round 2 survey questionnaire. 
This second survey will contain all items retained from 
round 1 (see Data analyses section) and anonymised feed-
back from the previous round in the form of summary 
scores (eg, median/mean scores depending on distribu-
tion) from all stakeholder groups separately to allow all 
stakeholder groups to see the results from others before 
re-scoring; a method observed to improve the degree 
of consensus reached.9 27 Participants will be asked to 
re-score each item’s importance. If there is insufficient 
consensus to proceed to a consensus meeting at the end 
of round 2, a third round may be conducted. Methods 
will be identical to those described for round 2. All items 
retained after the final Delphi survey round will be taken 
forward to the consensus meeting.
Methodological study exploring methods to optimise consensus
An embedded methodological study will explore optimal 
language for Delphi survey instructions. Participants will 
be randomly allocated to receive one of two versions of 
the round 1 survey questionnaire, which will differ only in 
the phrasing of the instructions provided for completing 
the questionnaire. Version A (standard instructions) 
will be phrased using common COS instruction termi-
nology (eg, asking respondents to score how important 
they think each outcome/item is to include in the COS). 
Version B (enhanced instructions) will use terminology 
to emphasise that respondents should prioritise as few 
outcomes/items as possible. Participants will be allocated 
at random to one of the two groups and blinded to their 
allocation to minimise bias. Results from round 1 (eg, 
the number and types of outcomes that are prioritised) 
will be compared between the two allocation groups. In 
subsequent survey rounds, all participants will receive 
the same version of the survey questionnaire containing 
enhanced instructions to encourage prioritisation.
Attrition between rounds
Participant attrition between rounds will be monitored 
and differences in scores between those who do and do 
not complete all survey rounds conducted.
Phase III: consensus meeting with key stakeholders to 
discuss and agree the final reporting guidance content and 
CoS(s)
The final step will be a face-to-face consensus meeting to 
discuss the results of the Delphi survey, agree on items 
that should be included, and approve the final guidance 
content and COS(s).9 13 A purposive sample of 20–25 
patient and professional participants who participated 
in at least one survey round will be invited, to ensure 
inclusion of patients with a range of experiences of 
different types of surgery and professionals with various 
professional backgrounds. A joint meeting for patients 
and professionals is planned to encourage discussion 
around outcomes that are scored differently by the two 
stakeholder groups, to share differing perspectives and 
thereby encourage consensus. Care will be taken to ensure 
that discussions are held using plain English language 
and that both patients and professional participants are 
empowered to express their views freely.
A summary of the survey results will be presented. Partic-
ipants will be asked to ratify the inclusion/exclusion of 
outcomes during the Delphi survey, and to anonymously 
re-score items for which objections have been raised or 
for which consensus was not reached during the Delphi 
survey (see Data analyses section). Further moderated 
discussion and re-scoring will be undertaken as neces-
sary until consensus has been reached. The meeting will 
be audio-recorded and transcribed verbatim. Another 
meeting will be considered should agreement on the final 
COS not be reached.
Sample size
Delphi survey sample sizes aim to achieve good represen-
tation from all key stakeholder groups.9 We aim to include 
approximately 150 professional participants and 50 
patient participants in the survey and 20–25 participants 
from all stakeholder groups in the consensus meeting. In 
qualitative research, an approximation of sample size is 
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Table 1 Definition of consensus
Category Definition Action
Consensus in Scored as very important (7–9) by ≥70% and 
not important (1–3) by <15% of either patients 
or professionals or both.
Item retained for next survey round/ 
consensus meeting.
Consensus out Scored as not important (1–3) by ≥70% and 
very important (7–9) by <15% of either patients 
or professionals or both.
Item discarded after round 2 (to be 
ratified at consensus meeting).
No consensus Neither criteria above are met. Item retained for next survey round/ 
consensus meeting.
considered necessary for planning. We anticipate that at 
least 25 interviews will be required to reach data satura-
tion, though adequacy of the final sample size will be eval-
uated throughout the study. A 3:1 ratio of professionals to 
patient participants is considered appropriate given that 
there are multiple professional stakeholder subgroups 
whose involvement in the development of the COS is 
warranted.
data analyses
Retaining or dropping items between survey rounds
All data will be entered and stored on the REDCap elec-
tronic data capture tool25 and exported into a statis-
tical software package for data cleaning and checking. 
Descriptive statistics will be calculated for each item (eg, 
summary scores, ranges, percentage scoring each item 
‘not important’ (score 1-3), ‘equivocal’ (4-6) and ‘very 
important’ (7–9)). All items will be retained between 
rounds 1 and 2.9 28 29 This approach will enable partici-
pants to re-score every item considering feedback from 
round 1 but reduce participant burden in subsequent 
rounds (if necessary) and at the consensus meeting.9 
Following round 2, items will be categorised as described 
in table 1.
A third round will be held if the number of COS 
items categorised as ‘consensus in’ or ‘no consensus’ is 
considered too large (eg, >30) to feasibly discuss at the 
consensus meeting. The same criteria to define consensus 
and retain/discard items as above will be used. Stake-
holder groups will be analysed separately in each round 
to negate the need to weight responses due to variation 
between sample sizes and to ensure that outcomes are 
not excluded prematurely. This methodology has been 
used in the development of other COS(s) to ensure that 
the outcome must be considered very important to the 
majority of participants to be included.9 28–30
Consensus meeting
Following the first round of voting, items will be catego-
rised as ‘consensus in’, ‘consensus out’ or ‘no consensus’ 
using the definitions of consensus as detailed in table 1. 
Items voted ‘consensus in’ will be included in the final 
COS and items voted ‘consensus out’ discarded. Discor-
dant items will be discussed further and re-scored in a 
second round of voting and the same criteria applied. 
Further rounds of discussion and voting will occur 
until consensus is achieved. The consensus meeting will 
conclude with asking participants to ratify the final COS.
Implementation of the CoS(s)
Key multinational stakeholders will be engaged 
throughout the guidance/COS development process to 
promote awareness, foster ownership of the project and 
encourage dissemination and uptake. Engagement with 
funders, journal editors, regulatory bodies, industry and 
other bodies (eg, UK NIHR Surgical MedTech Cooper-
ative, NIHR Office for Clinical Research Infrastructure) 
will seek to encourage and promote uptake in all studies 
of innovative invasive procedures/devices. We will also 
seek to involve these stakeholders and other interna-
tional professional bodies responsible for promoting safe 
and transparent innovation (eg, in the UK: The Royal 
College of Surgeons of England, specialty professional 
associations, IDEAL) to endorse the reporting guidance 
and COS(s) and to encourage use in research and clinical 
practice. Patient and public engagement will establish 
the importance of this work more widely and encourage 
adoption of the guidance and COS(s) into other relevant 
guidelines/recommendations. The aim is to incorporate 
the reporting guidance and COS(s) as part of a real-time 
reporting system for surgical innovation. We will work 
with regulatory bodies and professional associations to 
develop a platform (eg, surgical registries that prospec-
tively collect outcome and safety data) by which this may 
be achieved as the next steps of this work. Future work 
will also focus on how to measure the outcomes included 
in the COS(s).
This study was registered with the COMET Initiative on 
20/11/2017.
EthICS And dISSEMInAtIon
Ethical approval for this study has been granted by North 
East-Newcastle and North Tyneside 1 Health Research 
Authority Research Ethics Committee. Written informed 
consent will be obtained from participating patients 
separately for the Delphi survey and consensus meeting. 
Delphi survey registration via the study website and/or 
completion of the Delphi surveys by professional partici-
pants will be taken to imply consent. Written consent will 
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be obtained from professional participants prior to the 
consensus meeting.
Dissemination strategies include presentation at scien-
tific meetings, peer-reviewed journal publications, devel-
opment of plain English summaries and dissemination 
materials in collaboration with our PPI group, patient 
engagement events, development of a social media iden-
tity, workshops and other events.
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